Sanofi Adr Stock Today
| SNY Stock | USD 57.75 0.06 0.10% |
PerformanceSolid
| Odds Of DistressLow
|
Sanofi ADR is trading at 57.75 as of the 16th of March 2025; that is 0.10% increase since the beginning of the trading day. The stock's open price was 57.69. Sanofi ADR has less than a 9 % chance of experiencing financial distress in the next few years and had a solid performance during the last 90 days. Note, on September 6, 2024, Representative John James of US Congress acquired under $15k worth of Sanofi ADR's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of July 2002 | Category Healthcare | Classification Health Care |
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. Sanofi was founded in 1973 and is headquartered in Paris, France. Sanofi-Aventis operates under Drug ManufacturersGeneral classification in the United States and is traded on NASDAQ Exchange. The company has 2.51 B outstanding shares of which 5.46 M shares are at this time shorted by investors with about 2.38 days to cover. More on Sanofi ADR
Moving against Sanofi Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Sanofi Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President | JeanBaptiste Chatillon | ||||
| Thematic Ideas | Showing 3 out of 4 themes | ||||
| Old Names | [SCRIPPS NTWKS-A - Dusseldorf Stock Exchang, Scripps Networks Interactive Inc] | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, ARCA Pharmaceutical, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Giant Impact, Dividend Beast, Compulsion, Healthcare, Health Care, Pharmaceuticals, Drug Manufacturers—General, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsSanofi ADR can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sanofi ADR's financial leverage. It provides some insight into what part of Sanofi ADR's total assets is financed by creditors.
| |||||
Sanofi ADR (SNY) is traded on NASDAQ Exchange in USA. It is located in 46, avenue de la Grande Armée, Paris, France, 75017 and employs 82,878 people. Sanofi ADR is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with a total capitalization of 145.02 B. Sanofi ADR runs under Pharmaceuticals sector within Health Care industry. The entity has 2.51 B outstanding shares of which 5.46 M shares are at this time shorted by investors with about 2.38 days to cover.
Sanofi ADR has about 6.9 B in cash with 9.08 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.76.
Check Sanofi ADR Probability Of Bankruptcy
Ownership AllocationSanofi ADR shows a total of 2.51 Billion outstanding shares. About 89.41 % of Sanofi ADR outstanding shares are held by general public with 10.59 % by institutional holders. Please note that on September 6, 2024, Representative John James of US Congress acquired under $15k worth of Sanofi ADR's common stock.
Check Sanofi Ownership Details
Sanofi Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Franklin Resources Inc | 2024-12-31 | 3.8 M | |
| Nuveen Asset Management, Llc | 2024-12-31 | 3.7 M | |
| Mondrian Investment Partners Ltd | 2024-12-31 | 3.5 M | |
| Magnetar Financial Llc | 2024-12-31 | 3.3 M | |
| Envestnet Asset Management Inc | 2024-12-31 | 3.1 M | |
| Natixis Advisors, Llc. | 2024-12-31 | 2.9 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2.9 M | |
| Raymond James & Associates | 2024-09-30 | 2.8 M | |
| Bank Of New York Mellon Corp | 2024-12-31 | 2.8 M | |
| Dodge & Cox | 2024-12-31 | 75.2 M | |
| Fisher Asset Management, Llc | 2024-12-31 | 12.5 M |
Sanofi ADR Historical Income Statement
Sanofi Stock Against Markets
Sanofi ADR Corporate Management
| Roy Papatheodorou | Executive Counsel | Profile | |
| FranoisXavier Roger | Chief Officer | Profile | |
| Paul Hudson | CEO Director | Profile | |
| Madeleine Roach | Executive Operations | Profile | |
| Pierre Chancel | Senior Marketing | Profile | |
| Bruno Mnard | Chief officer | Profile | |
| Dante Beccaria | Global VP | Profile |
Additional Tools for Sanofi Stock Analysis
When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.